Cardiology

Top Story

New studies evaluate Jardiance in patients with chronic heart failure

April 30, 2016

Two new outcome trials will investigate the SGLT2 inhibitor Jardiance for the treatment of people with chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company said in a joint press release.

The trials are slated to begin in the next 12 months and are planned to enroll people with chronic heart failure both with and without type 2 diabetes.

Meeting News CoverageVideo

VIDEO: Vascular disease risks vary by sex

April 29, 2016
CHICAGO — In this video, Jeffrey S. Berger, MD, from the New York University School of Medicine, examines the association between age, sex and different…
FDA News

FDA approves first generic rosuvastatin

April 29, 2016
The FDA has approved the first generic rosuvastatin calcium tablets for the treatment of high triglycerides and high LDL, according to a press release.Watson…
In the Journals

Endovascular thrombolysis safe, viable for pediatric population

April 29, 2016
Pediatric patients with iliofemoral thrombosis can be treated with endovascular thrombolysis at a high technical success rate with few major complications, according to…
In the Journals

Unmet nursing care may lead to rehospitalizations for black patients with acute MI

April 29, 2016
Black patients with acute MI who do not receive all necessary nursing care are more likely than their white counterparts to be readmitted to the hospital within the…
More News Headlines »
CME Video

Secondary Prevention of Atherothrombotic Events: Current Insights on Advancing Science

This activity is supported by an educational grant from Merck & Co.

Prevention of cardiovascular disease (CVD) is critical in light of its associated mortality, morbidity, and economic…
More »
Video
Meeting News Coverage

VIDEO: Expert discusses ‘landmark’ TAVR trials

April 20, 2016
More »
Featured
Video
Meeting News Coverage

VIDEO: HEART Score displays real-world success in stratifying ACS risk, could curb resource use

April 25, 2016
More »